Jingle Bell JogZippity Doo Dah gives to BCHJackson Free ClinicCommencement 2014
  • Drew Hildebrandt, MD, Publications

    • Hildebrandt, D.A., and R.O. Banks. Effects of atrial natriuretic factor in rats with papillary necrosis. Am. J. Physiol. 252 (Renal, Fluid and Electrolyte Physiol. 21): F977-F980, 1987.
    • Hildebrandt, D.A., and R.O. Banks. Effects of atrial natriuretic factor on renal function in rats with nephrotic syndrome. Am. J. Physiol. 254 (Renal, Fluid and Electrolyte Physiol. 23): F210-F216, 1988.
    • Mizelle, H.L., J.E. Hall and D.A. Hildebrandt. Atrial natriuretic peptide and pressure natriuresis: interactions with the renin-angiotensin system. Am. J. Physiol. 257 (Regulatory, Integrative, Comp. Physiol. 26): R1169-R1174, 1989.
    • Hall, J.E., M.W. Brands, S.D. Kivlighn, H.L. Mizelle, D.A. Hildebrandt, and C.A. Gaillard. Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines? Hypertension 15: 519-527, 1990.
    • Mizelle, H.L., D.A. Hildebrandt, C.A. Gaillard, M.W. Brands, J-P. Montani, M.J. Smith, Jr., and J.E. Hall. Atrial natriuretic peptide indices sustained natriuresis in conscious dogs. Am. J. Physiol. 258 (Regulatory, Integrative, Comp. Physiol. 27): R1445-R1452, 1990.
    • Hall, J.E., H.L. Mizelle, D.A. Hildebrandt, and M.W. Brands. Abnormal pressure natriuresis: a cause or consequence of hypertension? Hypertension 15: 547-559, 1990.
    • Hildebrandt, D.A., H.L. Mizelle, M.W. Brands, C.A. Galliard, M.J. Smith, Jr., and J.E. Hall. Intrarenal atrial natriuretic peptide infusion lowers arterial pressure chronically. Am. J. Physiol. 259 (Regulatory, Integrative, Comp. Physiol. 28): R585-R592, 1990.
    • Gaillard, C.A., H.L. Mizelle, J-P. Montani, M.W. Brands, D.A. Hildebrandt and J.E. Hall. Role of atrial natriuretic factor in long-term blood pressure control: Role of sodium and aldosterone. Am. J. Physiol. 259 (Regulatory, Integrative, Comp. Physiol. 28): R973-R980, 1990.
    • Brands, M.W., H.L. Mizelle, C.A. Gaillard, D.A. Hildebrandt, and J.E. Hall. The hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am. J. Hyperten. 4: 164-168, 1991.
    • Hall,J.E., M.W. Brands, H.L. Mizelle, C.A. Gaillard, and D.A. Hildebrandt. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am. J. Physiol. 260 (Renal Fluid Electrolyte Physiol. 29): F663-F669, 1991.
    • Brands, M., D.A. Hildebrandt, H.L. Mizelle, and J.E. Hall. Sustained hyperinsulinemia increases arterial pressure in conscious rats. Am. J. Physiol. 260 (Regulatory, Integrative, Comp. Physiol. 29): R764-R768, 1991.
    • Brands, M.W., D.A. Hildebrandt, H.L. Mizelle, and D.A. Hildebrandt. Hypertension during chronic hyperinsulinemia in rats is not salt-sensitive. Hypertension 19[Suppl. I]: I-83-I89, 1992.
    • Hall, J.E., H.L. Mizelle, M.W. Brands,and D.A. Hildebrandt. Pressure natriuresis and angiotensin II in salt-induced hypertension. Am. J. Physiol. 262 (Regulatory, Integrative, Comp. 31): R61-R71, 1992.
    • Hildebrandt, D.A., H.L. Mizelle, M.W. Brands, and J.E. Hall. Comparison of the renal actions of urodilatin and atrial natriuretic peptide. Am. J. Physiol. 262 (Regulatory, Integrative, Comp. Physiol. 31): R395-R399, 1992.
    • Hall, J.E., M.W. Brands, D.A. Hildebrandt, and H.L. Mizelle. Obesity-associated hypertension: hyperinsulinemia and renal mechanisms. Hypertension 19 (Suppl. I): I45-I55, 1992.
    • Dwyer, T.M., K. Diveki, G. Newton, A. Szebini, D. Hildebrandt, and M. Petrini. Basal and thrombin-stimulated platelet calcium. Am. J. Hyperten. 7: 261-268, 1994.
    • Hall, J.E., M.W. Brands, D.H. Zappe, W.N. Dixon, H.L. Mizelle, G.A. Reinhart, and D.A. Hildebrandt. Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin resistant dogs. Hypertension 25: 994-1002, 1995.
    • Lohmeier, T.E., G.A. Reinhart, H.L. Mizelle, J-P. Montani, R.L. Hester, C.E. Hord, and D.A. Hildebrandt. Influence of the renal nerves on sodium excretion during progressive reductions in cardiac output. Am. J. Physiol. 269 (Regulatory, Integrative, Comp. Physiol. 38): R678-R690, 1995.
    • Reckelhoff, J.F., J.A. Kellum, Jr., L.C. Racusen, and D.A. Hildebrandt. Long-term dietary supplementation with L-arginine prevents age-related reduction in renal function. Am. J. Physiol 272 (Regulatory, Integrative, Comp. Physiol. 41): R1768-R1774, 1997.
    • Lohmeier, T.E., and D.A. Hildebrandt. Renal nerves promote sodium excretion in angiotensin-induced hypertension. Hypertension 31[part 2]:429-434, 1998.
    • Hildebrandt, D.A., M.J. Smith, Jr., and J.E. Hall. Cardiovascular regulation during insulin infusion into the carotid or vertebral artery in dogs. J. Hypertension 17(2):251-260, 1999.
    • Hall, J.E., M.W. Brands, D.A. Hildebrandt, J. Kuo, and S. Fitzgerald. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Brazilian J. Med. and Biol. Peptides 33(6):605-618, 2000.
    • Lohmeier, T.E., J.R. Lohmeier, A. Haque and D.A. Hildebrandt. Baroreflexes prevent neurally-induced sodium retention in angiotensin hypertension. Am. J. Physiol. 279 (Regulatory, Integrative, Comp. Physiol.):R1437-48, 2000.
    • Hall, J.E., D. A. Hildebrandt, and J. Kuo. Obesity hypertension-- role of leptin and sympathetic nervous system. Am. J. Hyperten. 14(6 Pt. 2):103S-115S, 2001.
    • Lohmeier, T.L., J.R. Lohmeier, J.F. Reckelhoff, and D.A. Hildebrandt. Sustained influence of the renal nerves to attenuate sodium retention in angiotensin hypertension. Am. J. Physiol. (Regulatory, Integrative, Comp. Physiol.) 281(2):R434-R443, 2001.
    • Summers, R.L., Z. Li, and D.A. Hildebrandt. Effect of a delta-receptor agonist on duration of survival during hemorrhagic shock. Acad. Emerg. Med. 10(6):587-593, 2003.
    • Lohmeier, T.E., D.A. Hildebrandt, S. Warren, P.J. May, and J. T. Cunningham. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am. J. Physiol. Regulatory, Integrative, Comp. Physiol. 288(4):R828-R836, 2005
    • Lohmeier, T.E., T.M. Dwyer, D.A. Hildebrandt, E.D. Irwin, M.A. Rossing, D.A. Serdar, and R.S. Kieval. Influence of angiotensin on the blood pressure lowering effects of prolonged baroreflex activation. Hypertension 46(5):1194-200, 2005.
    • Salameh JR, Schwartz J, Hildebrandt DA. Can Ligasureâ„¢ seal and divide small bowel? Am. J. Surgery 191(6):791-3, 2006.
    • Lohmeier, T.E., D.A. Hildebrandt, T.M. Dwyer, A.M. Barrett, E.D. Irwin, M.A. Rossing, R.S. Kieval. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 49: 373-379, 2007.
    • Lohmeier, TE, D.A. Hildebrandt, T. M. Dwyer, E.D. Irwin, A.W. Cates, and M.A. Rossing. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension 53(5):833-838, 2009.

    Abstracts

    • Hildebrandt, D.A. and R.O. Banks. Atrial natriuretic factor (ANF)-and furosemide-induced natriuresis in rats with papillary necrosis. Kidney Int. 29: 398, 1986.
    • Hildebrandt, D.A. and R.O. Banks. No effect of atrial natriuretic factor in rats with aminonucleoside-induced nephrotic syndrome. Kidney Int. 31: 272, 1987.
    • Hildebrandt, D.A. and R.O. Banks. Further characterization of atrial natriuretic factor (ANF) in aminonucleoside (AMN) treated rats. Fed. Proc. 46: 1280, 1987.
    • Mizelle, H.L., J.E. Hall, D.A. Hildebrandt, and C.D. Smith. Interactions between atrial natriuretic factor, pressure natriuresis, and the renin angiotensin system. Am. J. Hyperten. 1: 102A, 1988.
    • Mizelle, H.L., J.E. Hall, D.A. Hildebrandt, and J-P. Montani. Does atrial natriuretic peptide (ANP) cause chronic natriuresis? Kidney Int. 35: 285, 1989.
    • Smith, C.D., H.L. Mizelle, D.A. Hildebrandt, and J.E. Hall. Angiotensin-adenosine interactions in the renal vasculature: mechanisms of calcium activation. Kidney Int. 35: 474, 1989.
    • Hildebrandt, D.A., H.L. Mizelle, and J.E. Hall. Intrarenal infusion of atrial natriuretic peptide (ANP) lowers blood pressure chronically. FASEB Journal 3: A697, 1989.
    • Mizelle, H.L., J.E. Hall, D.A. Hildebrandt, and J.P. Montani. Renal hemodynamics and electrolyte excretion during chronic intrarenal infusion of atrial natriuretic peptide (ANP). FASEB Journal 3: A697, 1989.
    • Hall, J.E., M.W. Brands, S.D. Kivlighn, D.A. Hildebrandt, H.L. Mizelle, and C.A. Gaillard. Hyperinsulinemia, catecholamines, and long-term blood pressure regulation. Am. J. Hyperten. 2: 32A, 1989.
    • Gaillard, C.A., J.E. Hall, H.L. Mizelle, D.A. Hildebrandt, and J.P. Montani. Chronic low dose ANF infusion causes hypotension in sodium depleted dogs. Am. J. Hyperten. 2: 33A, 1989.
    • Gaillard, C.A., J.E. Hall, H.L. Mizelle, D.A. Hildebrandt, and J.P. Montani. Atrial natriuretic factor and long-term blood pressure control: interaction with renin-angiotensin-aldosterone system. Kidney Int. 37: 339, 1990.
    • Brands, M.W., J.E. Hall, D.A. Hildebrandt, and H.L. Mizelle. Hypertension during chronic hyperinsulinemia in conscious rats. FASEB Journal 4: A817, 1990.
    • Hall, J.E., H.L. Mizelle, M.W. Brands, and D.A. Hildebrandt. Salt-induced hypertension: role of pressure natriuresis. FASEB Journal 4: A817, 1990.
    • Hildebrandt, D.A., H.L. Mizelle, M.W. Brands, and J.E. Hall. Comparison of the renal actions of urodilatin (URO) and atrial natriuretic peptide (ANP). FASEB Journal 4: A695, 1990.
    • Mizelle, H.L., M.W. Brands, C.A. Gaillard, R.D. Manning, W.N. Dixon, D.A. Hildebrandt, and J.E. Hall. Chronic hemodynamic actions of atrial natriuretic peptide (ANP). FASEB Journal 4: A694, 1990.
    • Brands, M.W., H.L. Mizelle, C.A. Gaillard, D.A. Hildebrandt, and J.E. Hall. The hemodynamic response to chronic hyperinsulinemia in conscious dogs. Am. J. Hyperten. 3(5): 19A, 1990.
    • Hall, J.E., M.W. Brands, H.L. Mizelle, C.A. Gaillard, and D.A. Hildebrandt. Chronic intrarenal hyperinsulinemia and blood pressure regulation. Am. J. Hyperten. 3(5): 26A, 1990.
    • Brands, M.W., H.L. Mizelle, C.A. Gaillard, D.A. Hildebrandt, and J.E. Hall. Hemodynamic responses to chronic hyperinsulinemia. Proc. XI Internat. Soc. Hyperten. 160: 1990.
    • Hall, J.E., M.W. Brands, H.L. Mizelle, C.A. Gaillard, and D.A. Hildebrandt. Control of arterial pressure during chronic intrarenal or systemic hyperinsulinemia. J. Hypertension 8 (Suppl. 3): S9, 1990.
    • Hildebrandt, D.A., H.L. Mizelle, M.W. Brands, and J.E. Hall. Renal pressure natriuresis and urodilation: a new natriuretic hormone. J. Am. Soc. Nephrol. 1(4): 417, 1990.
    • Hall, J.E., W.N. Dixon, M.W. Brands, H.L. Mizelle, and D.A. Hildebrandt. Obesity, hyperinsulinemia, and hypertension: control of renal function and systemic hemodynamics. J. Am. Soc. Nephrol. 1(4): 490, 1990.
    • Mizelle, H.L., M.W. Brands, D.A. Hildebrandt, and J.E. Hall. Role of renal perfusion pressure in chronic hypercalcuria. J. Am. Soc. Nephrol. 1(4): 496, 1990.
    • Hall, J.E., M.W. Brands, W.N. Dixon, H.L. Mizelle, and D.A. Hildebrandt. Hyperinsulinemia does not elevate blood pressure in obese hypertensive dogs. FASEB Journal 5: A737, 1991.
    • Brands, M.W., J.E. Hall, H.L. Mizelle, and D.A. Hildebrandt. Chronic angiotensin converting enzyme inhibition (ACEI) improves cardiac output and fluid balance during heart failure. FASEB Journal 5: A738, 1991.
    • Hildebrandt, D.A., H.L. Mizelle, M.W. Brands, and J.E. Hall. Low salt diet abolishes the renal response to urodilatin (URO). FASEB Journal 5: A1019, 1991.
    • Brands, M.W., J.E. Hall, D.A. Hildebrandt, and H.L. Mizelle. Hypertension during chronic hyperinsulinemia in rats is not salt-sensitive. Am. J. Hyperten. 4: 13A, 1991.
    • Hall, J.E., M.W. Brands, W.N. Dixon, H.L. Mizelle, and D.A. Hildebrandt. Renal function in obesity-associated hypertension in conscious dogs. Am. J. Hyperten. 4: 118A, 1991.
    • Gupta, A.K., R.C. Atkinson, D.A. Hildebrandt, J.D. Bower, and K.A. Kirchner. Urodilatin (URO) but not atrial natriuretic peptide (ANP) increases sodium excretion (UNaV) in nephrotic rats. Clin. Res. 39(2): 359A, 1991.
    • Hildebrandt, D.A., B.N. Van Vliet, M.W. Brands, H.L. Mizelle, and J.E. Hall. Chronic intravertebral (IVT) angiotensin II (AII) infusion increases arterial pressure. FASEB J. 6: A1469, 1992.
    • Brands, M.W., M. Alonso-Galacia, H.L. Mizelle, D.A. Hildebrandt, and J.E. Hall. Renal perfusion pressure (RPP) and sodium balance in DOCA-salt hypertension. FASEB J. 6: A1469, 1992.
    • Hall, J.E., Brands, M.W., Dixon, W.N., Mizelle, H.L. and Hildebrandt, D.A. Blood pressure regulation during chronic hyperinsulinemia in obese insulin resistant dogs. Proc. XIV Meeting of Int .Soc. Hyperten.: 224, 1992.
    • Hildebrandt, D.A. Renal and systemic hemodynamic actions of long-term intravertebral (VT) angiotensin II (AII) infusion. J. Miss. Acad. Sci. 38: 45, 1993.
    • Lohmeier, T.E., G.A. Reinhart, H.L. Mizelle, J.-P. Montani, D.A. Hildebrandt, R.L. Hester, and C.E. Hord. Neurohormonal control of sodium excretion during controlled reductions in cardiac output. FASEB J. 7: A188, 1993.
    • Hildebrandt, D.A., H.L. Mizelle, M.W. Brands, and J.E. Hall. Systemic hemodynamic actions of long-term intravertebral (VT) angiotensin II (AII) infusion. FASEB J. 7: A405, 1993.
    • Hildebrandt, D.A., B.J. Heath, and J.E. Hall. Systemic arterial blood pressure and heart rate responses to acute and chronic carotid or vertebral artery insulin infusion. FASEB J. 8: A528, 1994.
    • Hildebrandt, D.A., J-P. Montani, B.J. Heath, and J.P. Granger. Chronic ouabain (OUA) infusion alters systemic hemodynamics in normal dogs. FASEB J. 9: A297, 1995.
    • Kirk, D., and D.A. Hildebrandt. Systemic arterial pressure (AP) responses to chronic vertebral artery (VA) angiotensin II (ANGII) infusion during adrengergic blockade (AB). J. Miss. Acad. Sci. 43:41, 1998.
    • Lohmeier, T.L., J.F. Reckelhoff, D.A. Hildebrandt, and W.A. Hood. Potential role of renal nitric oxide (NO) production in promoting sodium excretion in angiotensin-hypertension (ANGII-HT). FASEB J. 12(4):A363, 1998.
    • Hildebrandt, D.A., and D.A. Kirk. Systemic hemodynamic responses to chronic vertebral artery (VA) angiotensin II (ANGII) infusion during adrenergic blockade (AB). FASEB J., 12(4):A111, 1998.
    • Lohmeier, T.E., D.A. Hildebrandt, and W.A. Hood. Renal nerves promote sodium excretion during chronic increments in salt intake. Hypertension, 32:604, 1998.
    • Lohmeier, T.E., J.R. Lohmeier, and D.A. Hildebrandt. Long-term influence of cardio-pulmonary receptors on sodium excretion in angiotensin-hypertension (ANGII-HT). FASEB J. 13(4):A457, 1999.
    • Hildebrandt, D., D. Kirk, and J.E. Hall. Renal and cardiovascular responses to chronic increases in cerebrovascular free fatty acids (FFA). FASEB J. 13(5):A780, 1999.
    • Lohmeier, T.E., A. Haque, W.J. McManus, and D.A. Hildebrandt. Long-term influence of basal renal nerve activity on arterial pressure. FASEB J. 14(4):A373, 2000.
    • Lohmeier, T.L., J. Lohmeier, A. Haque, and D.A. Hildebrandt. Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Accepted for presentation at the 54th Annual Conference and Scientific Sessions of the Council for High Blood Pressure.
    • Hildebrandt, D., Z. Li, and R.L. Summers. Role of localized changes in myocardial metabolic rate in promoting cardiac instability. Submitted for presentation at the 73rd Scientific Sessions of The American Heart Association.
    • Summers, R.L., Z. Li, and D.A. Hildebrandt. Localized myocardial ischemic preconditioning results in global cardiac instability. Ann. Emergency Med. 36(4):S53, 2000.
    • Lohmeier, T.L., J.R. Lohmeier, A. Haque, and D.A. Hildebrandt. Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Hypertension 36(4):680, 2000.
    • Summers, R.L., Z. Li, and D.A. Hildebrandt. Regulation of myocardial oxygen consumption during coronary occlusion and reperfusion. Eur. J. Emergency Med., 2001.
    • Summers, R.L., Z. Li, and D.A. Hildebrandt. Preservation of cardiac function by δ1 receptor agonist during coronary occlusion. Acad. Emergency Med. 8(5):563, 2001.
    • Hildebrandt, D.A. Angiotensin II-nitric oxide interactions in long-term arterial pressure control. FASEB J. 16(5):A840, 2002.
    • Summers, R.L., Z. Li, and D.A. Hildebrandt. Effect of delta receptor agonist on duration of survival during hemorrhagic shock. Acad. Emergency Med., 9(5):504, 2002.
    • Sumrall, R., J. Penton, A. Smitherman, and D. Hildebrandt. Delta opioid agonist improves survival following hemorrhage in rats. J. Miss. Acad. Sci. 48(1):57, 2003.
    • Penton, J., A. Smitherman, R. Sumrall, D. Hildebrandt. Increased skin transplant survival with delta opioid agonist. J. Miss. Acad. Sci. 48(1):57-58, 2003.
    • Summers, R.L., Z. Li, and D. Hildebrandt. Comparison of the effects of DADLE and norepinephrine treatments on hemodynamics and survival in hemorrhagic shock. Acad. Emerg. Med. 10(5):463, 2003.
    • Hildebrandt, D.A., J. Henegar, J.E. Hall. Chronic increases in intrarenal Angiotensin II do not cause renal injury independent of hypertension. This was supposed to be published in Hypertension, 2003, but after the meeting it was decided not to publish the presented abstracts.
    • Lohmeier, T.L., T.M. Dwyer, D. A. Hildebrandt, E.D. Erwin, M.A. Rossing, D.J. Serdar, and R.S. Kieval. Suppression of the renin-angiotensin system contributes to the reduction in arterial pressure produced by prolonged baroreflex activation. Hypertension 44:500, 2004.
    • Lohmeier, T. E., D. A. Hildebrandt, A. M. Barrett, E. D. Irwin, M. A. Rossing, D. J. Serdar, and R. S. Kieval. Prolonged baroreflex activation decreases arterial pressure even in the absence of the renal nerves. J Am Soc Nephrol. 15:201A, 2004.
    • Lohmeier, T. E., D.A. Hildebrandt, D.A., A. M. Barrett, E. D. Irwin, M.A. Rossing, D. J. Serdar, and R.S. Kieval. The renal nerves are not essential for sustained baroreflex-mediated reductions in arterial pressure. Am. J. Hypertens. 18:130A, 2005.
    • Hildebrandt, D.A., T.E. Lohmeier, E.D. Erwin, M.A. Rossing, and R.S. Kieval. Influence of high salt intake on the chronic blood pressure lowering effects of the baroreflex. FASEB J. 20:A356, 2006.
    • Hildebrandt, D.A., T.E. Lohmeier, E.D. Erwin, M.A. Rossing, R.J. Cody, and R.S. Kieval. Th blood pressure lowering effects of prolonged baroreflex activation are not salt sensitive. J. Clin. Hypertens. 8:A207, 2006.
    • Lohmeier, T.E., D.A. Hildebrandt, T.M. Dwyer, A.M. Barrett, E.D. Erwin, M.A. Rossing, and R.S. Kieval. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension (in press, 2006).
    • Franks, J., J. Lemus, C.-S. Lee, D. Hildebrandt, and J. Ogle. Challenges in artificial propagation of tripletail, Lobotes surinamensis. Proceedings of the Annual Meeting of the U.S. Aquaculture Society, February, 2006.
    • Jesse, R.L., R.L. Summers, C.V. Pollack, W.F. Peacock, A.J. Minisi, S. Meyer, V. Bodecker, and D. Hildebrandt. Feasibility of remote measurements of left atrial pressure using an implanted intracardiac pressure sensor. Journal of Cardiac Failure (in press, 2006).
    • Peacock, W.F., R.L. Summers, R.L. Jesse, C.V. Pollack, A.J. Minisi, S. Meyer, V. Bodecker, and D. Hildebrandt. Feasibility of remote measurements of left atrial pressure using an implanted intracardiac pressure sensor. Journal of Cardiac Failure (in press, 2006).
    • Hildebrandt, D. A., T.E. Lohmeier, E.D. Irwin, M.A. Rossing, and R.S. Kieval. Influence of high salt intake on the chronic blood pressure lowering effects of the baroreflex. FASEB J. 20:A356, 2006.
    • Hildebrandt, D. A., T.E. Lohmeier, E.D. Irwin, M.A. Rossing, R.J. Cody, and R.S. Kieval. The blood pressure lowering effects of prolonged baroreflex activation are not salt sensitive. J Clin Hypertens. 8:A207, 2006.
    • Lohmeier, T.E., D.A. Hildebrandt, T.M. Dwyer, A.M. Barrett, E.D. Irwin, M.A. Rossing, and R.S. Kieval. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 48:e31, 2006.
    • Hildebrandt, D.A., T.E. Lohmeier, T.M. Dwyer, E.D. Irwin, M.A. Rossing, and R.S. Kieval. Prolonged activation of the baroreflex decreases arterial pressure in the presence of chronic adrenergic blockade. FASEB J. 21:A516, 2007.
    • Lohmeier, T.E., D.A. Hildebrandt, T.M. Dwyer, E.D. Irwin, M.A. Rossing, and R.S. Kieval. Prolonged activation of the baroreflex abolishes reduced kidney mass, salt-induced hypertension. Hypertension:e-85, 2007.
    • Lohmeier, T.E., D.A. Hildebrandt, T.M. Dwyer, R. Iliescu, E.D. Irwin, A.W. Cates, M.A. Rossing. Decreased activation of postsynaptic alpha2-adrenoceptors contributes to the chronic blood pressure lowering effects of the carotid baroreflex during adrenergic blockade. Hypertension 52:e-44, 2008.
    • Vick, L.R., D.A. Hildebrandt and A.B. Wysocki. Wound healing in animal models: a comparative study of normal skin. Wound Rep Reg 17:A82, 2009.